secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001193125-25-335267
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM
--------------------------------------------------------------------------------

- Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.
- Prior $20M ATM program with Cantor Fitzgerald terminated effective Dec 17, 2025; Cantor waived 60-day restriction.
- Net proceeds intended for pipeline development, general corporate and working capital purposes.
- Agent fee up to 3% of gross proceeds; program may be terminated by either party on 10 days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312525335267/0001193125-25-335267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312525335267/sabs-20251229.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-335267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer